Kunyu Yang

10.5k total citations · 3 hit papers
173 papers, 4.6k citations indexed

About

Kunyu Yang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kunyu Yang has authored 173 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 57 papers in Molecular Biology and 53 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kunyu Yang's work include Head and Neck Cancer Studies (29 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Lung Cancer Treatments and Mutations (20 papers). Kunyu Yang is often cited by papers focused on Head and Neck Cancer Studies (29 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Lung Cancer Treatments and Mutations (20 papers). Kunyu Yang collaborates with scholars based in China, United States and Hong Kong. Kunyu Yang's co-authors include Chao Wan, Gang Wu, Gang Wu, Honglin Jin, Jonathan F. Lovell, Sheng Zhang, Tao� Zhang, Yajie Sun, Gang Peng and Qin Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Kunyu Yang

160 papers receiving 4.5k citations

Hit Papers

A prospective, randomized study comparing outcomes and to... 2012 2026 2016 2021 2012 2021 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma
    2012 466 citations Kunyu Yang, Tao� Zhang et al. profile →
  2. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Xinmin Yu, Chunhong Hu et al. profile →
  3. Ferroptosis‐Enhanced Immunotherapy with an Injectable Dextran‐Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma
    2023 71 citations Jingshu Meng, Yan Hu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kunyu Yang China 36 1.7k 1.5k 1.5k 831 697 173 4.6k
Eun Kyung Choi South Korea 41 1.9k 1.2× 1.8k 1.2× 1.7k 1.2× 772 0.9× 441 0.6× 259 6.2k
Luitpold Distel Germany 36 1.7k 1.0× 775 0.5× 1.3k 0.9× 526 0.6× 1.2k 1.7× 186 4.2k
Randall J. Kimple United States 35 1.4k 0.8× 650 0.4× 2.3k 1.6× 535 0.6× 418 0.6× 171 4.7k
Marc Mareel Belgium 27 1.4k 0.9× 574 0.4× 1.7k 1.1× 761 0.9× 460 0.7× 47 3.9k
Neil Senzer United States 43 3.9k 2.4× 1.6k 1.1× 3.6k 2.5× 1.0k 1.2× 1.2k 1.8× 176 7.8k
Nils Cordes Germany 40 1.9k 1.1× 615 0.4× 2.2k 1.5× 815 1.0× 365 0.5× 132 4.5k
Nikolai N. Khodarev United States 36 2.6k 1.5× 1.2k 0.8× 2.0k 1.4× 1.1k 1.3× 1.8k 2.6× 82 5.3k
Claire Vanpouille‐Box United States 30 3.2k 1.9× 1.1k 0.7× 1.3k 0.9× 667 0.8× 2.7k 3.8× 68 5.4k
Sandra Nuyts Belgium 48 1.2k 0.7× 1.8k 1.2× 989 0.7× 643 0.8× 124 0.2× 220 6.7k
David E. Wazer United States 51 2.6k 1.6× 1.2k 0.8× 2.2k 1.5× 3.8k 4.6× 373 0.5× 266 8.6k

Countries citing papers authored by Kunyu Yang

Since Specialization
Citations

This map shows the geographic impact of Kunyu Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunyu Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunyu Yang more than expected).

Fields of papers citing papers by Kunyu Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunyu Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunyu Yang. The network helps show where Kunyu Yang may publish in the future.

Co-authorship network of co-authors of Kunyu Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Kunyu Yang. A scholar is included among the top collaborators of Kunyu Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunyu Yang. Kunyu Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yin, Yingkai, et al.. (2024). The impact of enterprise digital transformation on financial mismatch: Empirical evidence from listed companies in China. Finance research letters. 66. 105677–105677. 9 indexed citations
3.
Liang, Zhiqiang, et al.. (2024). The Impact of High-Tech Enterprise Certification on Green Innovation: Evidence from Listed Companies in China. Sustainability. 17(1). 147–147. 2 indexed citations
4.
Li, Heng, Bin Qin, Shuyang Dai, et al.. (2024). Feasibility study of multiple‐energy Bragg peak proton FLASH on a superconducting gantry with large momentum acceptance. Medical Physics. 51(3). 2164–2174. 7 indexed citations
5.
Pang, Bo, et al.. (2024). Evaluation of an automated clinical decision system with deep learning dose prediction and NTCP model for prostate cancer proton therapy. Physics in Medicine and Biology. 69(11). 115056–115056. 2 indexed citations
6.
Liu, Furong, Xichun Hu, Jian Zhang, et al.. (2024). The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study. Journal of Hematology & Oncology. 17(1). 118–118. 6 indexed citations
7.
8.
9.
Zhang, Panpan, Yanru Qin, Jifang Gong, et al.. (2024). A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2590–2590. 1 indexed citations
10.
Hu, Yan, Chao Wan, Yang Xiao, et al.. (2023). Radiated tumor cell-derived microparticles effectively kill stem-like tumor cells by increasing reactive oxygen species. Frontiers in Bioengineering and Biotechnology. 11. 1156951–1156951. 2 indexed citations
11.
Sun, Yajie, Yu Tian, Ai Huang, et al.. (2023). Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity. Cell Reports Medicine. 4(12). 101303–101303. 9 indexed citations
12.
Xu, Guojie, Lei Zhao, Qingling Hua, et al.. (2023). CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway. Cell Death and Disease. 14(2). 167–167. 13 indexed citations
13.
Yang, Yun, Mingxing Xie, Li Zhang, et al.. (2022). Characteristics of older-patient-specif ic oncological trials: a cross-sectional analysis of ClinicalTrials.gov. Age and Ageing. 51(4). 2 indexed citations
14.
Jie, Xiaohua, Zilong Wu, Xinrui Rao, et al.. (2022). REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis. Cell Death and Disease. 13(2). 110–110. 10 indexed citations
15.
Sun, Yajie, Yan Hu, Chao Wan, et al.. (2021). Local biomaterial-assisted antitumour immunotherapy for effusions in the pleural and peritoneal cavities caused by malignancies. Biomaterials Science. 9(19). 6381–6390. 10 indexed citations
16.
Wan, Chao, Yajie Sun, Yu Tian, et al.. (2020). Irradiated tumor cell–derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Science Advances. 6(13). eaay9789–eaay9789. 189 indexed citations
17.
He, Qianyuan, Zhanjie Zhang, Haojie Liu, et al.. (2020). Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery. Nanoscale. 12(27). 14788–14800. 15 indexed citations
18.
Cao, Jiali, Guosong Wang, Mingfeng Wang, et al.. (2019). Nanobody-based sandwich reporter system for living cell sensing influenza A virus infection. Scientific Reports. 9(1). 15899–15899. 16 indexed citations
19.
Jin, Honglin, Chao Wan, Zhenwei Zou, et al.. (2018). Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel. ACS Nano. 12(4). 3295–3310. 178 indexed citations
20.
Zhang, Liling, Sabine Riethdorf, Gang Wu, et al.. (2012). Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. Clinical Cancer Research. 18(20). 5701–5710. 292 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eun Kyung Choi Breakdown of academic impact, for papers by Luitpold Distel Breakdown of academic impact, for papers by Randall J. Kimple Breakdown of academic impact, for papers by Marc Mareel Breakdown of academic impact, for papers by Neil Senzer Breakdown of academic impact, for papers by Nils Cordes Breakdown of academic impact, for papers by Nikolai N. Khodarev Breakdown of academic impact, for papers by Claire Vanpouille‐Box Breakdown of academic impact, for papers by Sandra Nuyts Breakdown of academic impact, for papers by David E. Wazer
Rankless by CCL
2026